Merck’s targeted Kelun-Biotech lung cancer drug sharply cut tumor progression risk in Phase 3 study
Merck and Kelun-Biotech’s Phase 3 trial showed sacituzumab tirumotecan plus KEYTRUDA cut tumor progression risk by 65% in advanced lung cancer patients.
Read More